Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1613-1619

  Nestal De Moraes, Gabriela ^a   Silva, Karina Lani ^a   Vasconcelos, Flavia Da Cunha ^a   Maia, Raquel Ciuvalschi ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Apoptosis; Chemoresistance; Idarubicin; Leukemia; Survivin

Indexed keywords

CASPASE 3; CASPASE 9; DOXORUBICIN; IDARUBICIN; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROTECTION; CELL STRAIN K 562; CELL STRUCTURE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; IDARUBICIN; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHENOTYPE; UP-REGULATION;

EID: 79954462657     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1224     Document Type: Article

References (45)

1. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002. (Pubitemid 34161136)
2. Hunter AM, LaCasse EC and Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12: 1543-1568, 2007. (Pubitemid 47106887)
3. Krepela E, Dankova P, Moravcikova E, et al: Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 35: 1449-1462, 2009.
4. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997 (Pubitemid 27353455)
5. Zaffaroni N, Pennati M and Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med 9: 360-372, 2005
6. Yamamoto H, Ngan CY and Monden M: Cancer cells survive with survivin. Cancer Sci 99: 1709-1714, 2008.
7. Li F, Ambrosini G, Chu EY, Plescia J, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998. (Pubitemid 28563719)
8. Zangemeister-Wittke U and Simon HU: An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle 3: 1121-1123, 2004 (Pubitemid 40268627)
9. Altieri DC: The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18: 609-615, 2006.
10. Pennati M, Folini M and Zaffaroni N: Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28: 1133-1139, 2007. (Pubitemid 47062670)
11. Mori A, Wada H, Nishimura Y, et al: Expression of the anti-apoptosis gene survivin in human leukemia. Int J Hematol 75: 161-165, 2002. (Pubitemid 43014079)
12. Badran A, Yoshida A and Wano S: Expression of the anti-apoptotic gene survivin in chronic myeloid leukemia. Anticancer Res 23: 589-592, 2003. (Pubitemid 36358456)
13. Conte E, Stagno F, Guglielmo P, et al: Survivin expression in chronic myeloid leukemia. Cancer Lett 225: 105-110, 2005. (Pubitemid 40740215)
14. Silver RT: The blast phase of chronic myeloid leukaemia. Best Pract Res Clin Haematol 22: 387-394, 2009.
15. Tallman MS, Gilliland DG and Rowe JM: Drug therapy for acute myeloid leukemia. Blood 106: 1154-1163, 2005. (Pubitemid 41130866)
16. Lambertenghi-Deliliers G, Annaloro C, Cortellaro M, et al: Idarubicin in blastic crisis of chronic myelogenous leukemia. Haematologica 76: 406-408, 1991.
17. Schneller F, Schuler M, Schumacher K, et al: Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia-results of a phase-II trial. Ann Hematol 77: 225-229, 1998. (Pubitemid 28550032)
18. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al: A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 48: 283-289, 2007. (Pubitemid 46994877)
19. Pytel D, Wysocki T and Majsterek I: Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance. Comp Biochem Physiol C Toxicol Pharmacol 144: 85-92, 2006. (Pubitemid 44301965)
20. Blasiak J, Gloc E, Wozniak K, et al: Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chem Biol Interact 140: 1-18, 2002. (Pubitemid 34606848)
21. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
22. Belloc F, Belaud-Rotureau MA, Lavignolle V, et al: Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells. Cytometry 40: 151-160, 2000. (Pubitemid 30322378)
23. Vial JP, Belloc F, Dumain P, et al: Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Leuk Res 21: 163-172, 1997. (Pubitemid 27141868)
24. Lotfi K, Zackrisson AL and Peterson C: Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett 178: 141-149, 2002. (Pubitemid 34178538)
25. Li F: Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92: 212-216, 2005.
26. Notarbartolo M, Cervello M, Dusonchet L, et al: Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 180: 91-101, 2002.
27. Vermeulen K, Van Bockstaele DR and Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann Hematol 84: 627-639, 2005.
28. Chiou SK, Jones MK and Tarnawski AS: Survivin-an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 9: 25-29, 2003.
29. Beardmore VA, Ahonen LJ, Gorbsky GJ and Kallio MJ: Survivin dynamics increases at centromeres during GS/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity. J Cell Sci 117: 4033-4042, 2004. (Pubitemid 39328292)
30. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
31. Altieri DC: New wirings in the survivin networks. Oncogene 27: 6276-6284, 2008.
32. Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005, 2008.
33. Carter BZ, Wang RY, Schober WD, et al: Targeting survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2: 488-493, 2003.
34. Gu CM, Zhu YK, Ma YH, et al: Knockdown of survivin gene by vector-based short hairpin RNA technique induces apoptosis and growth inhibition in Burkitt's lymphoma Raji cell line. Neoplasma 53: 206-212, 2006.
35. Jin HO, Yoon SI, Seo SK, et al: Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol 72: 1228-1236, 2006.
36. Sato A, Ito K, Asano T, et al: Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake. Int J Oncol 30: 695-700, 2007.
37. Zhen HN, Li LW, Zhang W, et al: Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol 31: 1111-1117, 2007.
38. Reiffers J, Huguet F, Stoppa AM, et al: A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 10: 389-395, 1996. (Pubitemid 26128775)
39. Chandele A, Prasad V, Jagtap JC, et al: Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6: 29-40, 2004. (Pubitemid 38391947)
40. Durrieu F, Belaud-Rotureau MA, Lacombe F, et al: Synthesis of Bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic cell lines. Cytometry 36: 140-191, 1999.
41. Kwee JK, Luque DG, Ferreira AC, et al: Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation. Anticancer Drugs 19: 975-981, 2008.
42. Maia RC, Vasconcelos FC, de Sá Bacelar T, et al: LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2- butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells. Invest New Drugs: May 25, 2010 (Epub ahead of print).
43. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70, 2008.
44. Liu FT, Kelsey SM, Newland AC and Jia L: Generation of reactive oxygen species is not involved in idarubicin-induced apoptosis in human leukeamic cells. Br J Haematol 115: 817-825, 2001. (Pubitemid 34042899)
45. Carvalho A, Carmena M, Sambade C, et al: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116: 2987-2998, 2003. (Pubitemid 36926987)